Priothera
PrivateLast Round
Series B
Feb 3, 2026
Total Funding Raised
$98.27M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Priothera operates in Healthcare & Life Sciences and is based in Dublin. Its latest recorded funding round was a Series B round in February 2026.
Priothera is a biotechnology company that develops S1P receptor modulators to improve outcomes for patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Priothera Comparables
Compare Priothera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bristol Myers Squibb | 69% | |
| MaaT Pharma | 68% | |
| Incyte Corporation | 67% |
For institutional investors. Book with your work email.
Priothera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 3, 2026 | ||||
| Grant | Jul 11, 2025 | ||||
| Grant | Jun 24, 2024 | ||||
| Debt | Apr 4, 2022 | ||||
| Debt | Feb 23, 2022 | ||||
Series A | Oct 12, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Priothera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 4see ventures | Series B |
| Fountain Healthcare Partners | Series B, Series A |
| HealthCap | Series B, Series A |
| European Investment Bank Group | Debt |
| Tekla Capital Management | Series A |
| Earlybird Venture Capital | Series B, Series A |
| European Union | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 19, 2026
Grew 15% QoQ, from 26 to 30 employees.
- Jul 26, 2026
Monthly visitors increased 35% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresSep 3, 2026
Priothera Ltd. appoints Dr Nigel Clark as Chief Business Officer to lead strategic partnering for mocravimod, as it advances the therapy through pivotal Phase 3 development, in France and Ireland on Sep 3rd '26.
For institutional investors. Book with your work email.
Priothera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Priothera's valuation, stock price, and market status.
Is Priothera a public or private company?
Priothera is a private company.
What is the current stock price of Priothera?
Priothera is a private company, so its shares have no public market price. Caplight tracks Priothera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Priothera worth (valuation)?
Valuation information for Priothera is not publicly available.
Can I buy Priothera stock?
Priothera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Priothera's last funding round?
Priothera's most recent funding round was Series B on February 3, 2026.
Who are the main investors in Priothera?
Key investors in Priothera include 4see ventures, Fountain Healthcare Partners, HealthCap, Bpifrance.
Will Priothera IPO soon?
No public IPO plans have been announced for Priothera.
How can I track Priothera secondary market activity?
Caplight tracks bids, offers, and trades in Priothera's shares on secondary markets.